Exelixis Inc Quick Ratio (EXEL) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Exelixis Inc   (NASDAQ: EXEL)

Exelixis Inc 's Quick Ratio

EXEL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Exelixis Inc 's Cash & cash equivalent grew by 8 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Exelixis Inc 's Quick Ratio to 2.32, Quick Ratio remained below Exelixis Inc average.

Within Biotechnology & Pharmaceuticals industry 84 other companies have achieved higher Quick Ratio than Exelixis Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1122 to 1296.

Explain Quick Ratio?
How much Cash & cash equivalents EXEL´s has?
What are EXEL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EXEL Quick Ratio (Jul 03 2026)
Q2		 (Apr 03 2026)
Q1		 (Jan 02 2026)
Q4		 (Oct 03 2025)
Q3		 (Jul 04 2025)
Q2
Y / Y Current Liabilities Change 7.68 % -7.05 % 0.46 % -5.22 % -2.77 %
Y / Y Cash & cash equivalent Change 6.1 % -24.64 % -4.7 % -16.87 % -21.05 %
Quick Ratio MRQ 2.32 2.1 2.61 2.64 2.35
EXEL's Total Ranking # 1296 # 1122 # 111 # 691 # 849
Seq. Current Liabilities Change -2.44 % -8.55 % 8.53 % 11.21 % -15.78 %
Seq. Cash & cash equivalent Change 8 % -26.62 % 7.14 % 24.96 % -23.29 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 85
Healthcare Sector # 467
Overall Market # 1296


Quick Ratio Statistics
High Average Low
19.98 4.2 0.75
(Mar 31 2013)   (Dec 31 2010)




Financial Statements
Exelixis Inc 's Current Liabilities $ 362 Millions Visit EXEL's Balance sheet
Exelixis Inc 's Cash & cash equivalent $ 839 Millions Visit EXEL's Balance sheet
Source of EXEL's Sales Visit EXEL's Sales by Geography


Cumulative Exelixis Inc 's Quick Ratio

EXEL's Quick Ratio for the trailling 12 Months

EXEL Quick Ratio

 (Jul 03 2026)
12 Months		 (Apr 03 2026)
12 Months		 (Jan 02 2026)
12 Months		 (Oct 03 2025)
12 Months		 (Jul 04 2025)
12 Months
Y / Y Current Liabilities TTM Growth -1.37 % -3.66 % -0.14 % 0.36 % 2.92 %
Y / Y Cash & cash equivalent TTM Growth -11.12 % -16.56 % -9.28 % -5.48 % 1.45 %
Quick Ratio TTM 2.42 2.43 2.56 2.59 2.69
Total Ranking TTM # 3971 # 2908 # 641 # 2399 # 2397
Seq. Current Liabilities TTM Growth 1.74 % -1.86 % 0.12 % -1.34 % -0.62 %
Seq. Cash & cash equivalent TTM Growth 1.34 % -6.57 % -1.33 % -4.87 % -4.87 %

Quick ratio ranking by company, industry and sector >> Back to EXEL Financial Strength Comparisons >> Go to Compare EXEL Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q2 2026 to $361.93 millions, cumulative Quick Ratio decreased to 2.42 above the EXEL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Exelixis Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2908 to 3971.

Explain Quick Ratio?
How much Cash & cash equivalents EXEL´s has?
What are EXEL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 142
Healthcare Sector # 896
Within the Market # 3971


trailing twelve months Quick Ratio Statistics
High Average Low
3.27 1.57 0.48
(Jun 28 2019)   (Dec 31 2011)




Companies with similar Quick Ratio in the quarter ending Jul 03 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJul 03 2026 MRQ Cash & cash equivalentJul 03 2026 MRQ Current Liabilities
Caribou Biosciences Inc   6.33 $ 113.800  Millions$ 17.974  Millions
Cognition Therapeutics inc   6.24 $ 34.012  Millions$ 5.450  Millions
C4 Therapeutics Inc   6.24 $ 300.854  Millions$ 48.247  Millions
Repligen Corp  5.94 $ 810.449  Millions$ 136.403  Millions
Cabaletta Bio Inc   5.64 $ 225.101  Millions$ 39.910  Millions
Revolution Medicines Inc   5.54 $ 3,937.969  Millions$ 710.589  Millions
Humacyte Inc   5.35 $ 79.903  Millions$ 14.948  Millions
Invivyd Inc   5.16 $ 160.080  Millions$ 31.028  Millions
Lineage Cell Therapeutics Inc   5.13 $ 50.855  Millions$ 9.914  Millions
Alector Inc   5.05 $ 172.798  Millions$ 34.236  Millions
Atyr Pharma Inc   5.04 $ 57.418  Millions$ 11.396  Millions
Vericel Corporation  5.04 $ 264.531  Millions$ 52.532  Millions
Inhibrx Biosciences Inc   4.75 $ 133.344  Millions$ 28.064  Millions
Replimune Group Inc   4.57 $ 195.328  Millions$ 42.767  Millions
Recursion Pharmaceuticals Inc   4.55 $ 545.683  Millions$ 119.886  Millions
Prime Medicine Inc   4.50 $ 142.720  Millions$ 31.692  Millions
Immunitybio inc   4.50 $ 357.371  Millions$ 79.392  Millions
Dbv Technologies S a   4.37 $ 174.900  Millions$ 40.000  Millions
Metagenomi Therapeutics Inc   4.37 $ 120.700  Millions$ 27.632  Millions
Alpha Cognition Inc.  4.37 $ 41.443  Millions$ 9.493  Millions
Intensity Therapeutics Inc   4.23 $ 9.500  Millions$ 2.245  Millions
Ginkgo Bioworks Holdings Inc   4.15 $ 302.163  Millions$ 72.740  Millions
Dyadic International Inc   4.13 $ 16.047  Millions$ 3.883  Millions
Tenaya Therapeutics Inc   4.11 $ 78.100  Millions$ 19.021  Millions
Vir Biotechnology Inc   4.08 $ 530.522  Millions$ 130.177  Millions
Adaptive Biotechnologies Corporation  3.92 $ 344.255  Millions$ 87.712  Millions
Immunocore Holdings Plc  3.74 $ 880.211  Millions$ 235.198  Millions
Entera Bio Ltd   3.50 $ 11.309  Millions$ 3.235  Millions
Exozymes Inc   3.49 $ 5.653  Millions$ 1.618  Millions
Acumen Pharmaceuticals Inc   3.44 $ 160.954  Millions$ 46.848  Millions

Date modified: 2026-09-13T23:29:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.